Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Diagnostics » Molecular Diagnostics » Oncotype DX Predicts Outcomes in Men With Unfavorable Intermediate-Risk Prostate Cancer, Study Finds

Oncotype DX Predicts Outcomes in Men With Unfavorable Intermediate-Risk Prostate Cancer, Study Finds

Jun 30, 2020
|
Christie Rizk
Premium

NEW YORK – Two new studies are highlighting the utility of Exact Sciences' Oncotype DX Genomic Prostate Score (GPS) assay as an independent predictor of disease outcomes in two different populations: patients with unfavorable intermediate (UFI)-risk prostate cancer, and African American men.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.
Oct
29
Featured Webinar

How to Train Your DRAGEN for Pathology Informatics

Sponsored by
Illumina

Illumina’s BaseSpace Sequence Hub (BSSH) supports primary and secondary analysis of massively parallel sequencing data and can be applied to gene panel data that is generated as part of a clinical cancer assay performed in a pathology lab.

Nov
03
Featured Webinar

A Streamlined Targeted NGS Workflow for Comprehensive Genomic Profiling of Different Tumor Samples

Sponsored by
Agilent

Molecular tumor profiling has provided extensive value, both in tumor biology and oncology, with the development of new technologies to identify biomarkers.

Nov
05
Featured Webinar

Beyond Traditional Biopsy for Esophageal Cancer: Novel Sampling Methods to Improve Patient Care

Sponsored by
Roche

This webinar will provide an overview of novel proximal and distal sampling methods that have promise to improve patient outcomes from esophageal cancer.

Nov
09
Featured Webinar

The Tumor Neighborhood Watch: How Spatial Architecture and Cellular Neighborhoods Correlate to Colorectal Cancer Outcomes

Sponsored by
Akoya Biosciences

Most recent single-cell and spatial biology studies have focused on the network of interactions between different cell types and their spatial context. 

What's Popular?

In Cancer

  1. Exact Sciences to Acquire Thrive Earlier Detection for up to $2.15B; Q3 Revenues Spike 87 Percent

  2. FDA Approves Foundation Medicine CDx, Bayer's Vitrakvi for NTRK Patients

  3. FDA Approves Foundation Medicine Liquid Biopsy Test as CDx for Three Targeted Therapies

  4. Melanoma Treatment Stage Affects Ability of Liquid Biopsy to Predict Immunotherapy Benefit

    Premium

  5. Caris Life Sciences Raises $310M Through Equity, Debt Financing

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.